Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
2025-06-10 23:52
Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
2025-06-10 09:00
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
2025-06-09 14:51
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
2025-06-09 14:16
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
2025-06-07 11:36
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
2025-06-06 16:12
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
2025-06-06 14:00
Kelun-Biotech Announces Approximately US$250 Million Placement
2025-06-06 11:04
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
2025-06-04 08:00
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
2025-06-04 06:30
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2025-06-03 14:00
International Healthcare Week 2025 - Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
2025-06-02 10:59
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
2025-06-02 09:00
Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration
2025-05-30 05:05
Dx&Vx Accelerates Development of Universal COVID-19 Vaccine
2025-05-29 21:03
Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025
2025-05-29 20:00
AI Meets Audit Powerhouse: Qualifyze Launches Quality Insights Platform to Help Global Pharma Manage Supplier Site Risk
2025-05-29 18:23
CPHI & PMEC China Sees Surge in International Attendance as Global Pharma Trade Outlook Strengthens
2025-05-29 12:43
Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
2025-05-29 10:23
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
2025-05-28 14:13